ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $13.46 to $14.97
• 50-Day Range: $13.50 to $18.35
• 52-Week Range: $10.00 to $18.90
• Volume: 3.13 million shs
• Average Volume: 1.80 million shs
• Market Capitalization: $1.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Buy

ARS Pharmaceuticals Stock Analysis - MarketRank™

ARS Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 555th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ARS Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ARS Pharmaceuticals is -27.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ARS Pharmaceuticals is -27.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ARS Pharmaceuticals has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.59% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently increased by 3.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ARS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ARS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.59% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently increased by 3.23%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.08

News Sentiment

ARS Pharmaceuticals has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for ARS Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,773,760.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRY Stock Analysis - Frequently Asked Questions

How have SPRY shares performed this year?

ARS Pharmaceuticals' stock was trading at $10.55 at the beginning of the year. Since then, SPRY shares have increased by 28.0% and is now trading at $13.50.

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) issued its earnings results on Wednesday, August, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.05. The firm had revenue of $15.72 million for the quarter, compared to analysts' expectations of $12.92 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 21.85% and a negative net margin of 42.74%.
Read the conference call transcript.

Who are ARS Pharmaceuticals' major shareholders?

ARS Pharmaceuticals' top institutional investors include Alliancebernstein L.P. (3.90%), Franklin Resources Inc. (1.86%), Adage Capital Partners GP L.L.C. (1.76%) and Aberdeen Group plc (1.53%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Justin Chakma, Alexander A Fitzpatrick, Eric Karas, Kathleen D Scott, Brian Dorsey, Peter A Thompson and Brent L Saunders.
View institutional ownership trends.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ARS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/24/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRY
• CIK: 1671858
• Web: ars-pharma.com
• Phone: 206-456-2900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ARS Pharmaceuticals: $31.00
• High Price Target: $40.00
• Low Price Target: $27.00
• Potential Upside/Downside: +129.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8 million
• Net Margins: -42.74%
• Pretax Margin: -42.49%
• Return on Equity: -21.85%
• Return on Assets: -15.88%

Debt

• Debt-to-Equity Ratio: 0.37
• Current Ratio: 6.17
• Quick Ratio: 5.98

Sales & Book Value

• Annual Sales: $112.34 million
• Price / Sales: 11.88
• Cash Flow: $0.01 per share
• Price / Cash Flow: 1,594.18
• Book Value: $1.95 per share
• Price / Book: 6.92

Miscellaneous

• Outstanding Shares: 98,826,000
• Free Float: 65,719,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: 0.90